RPL17 and malignant colon neoplasm: In a clinical study conducted in 2020, pembrolizumab, an anti-PD-1 agent, exhibited significant improvements in PFS (16.5 vs. 8.2 months) compared to standard treatments as a first-line therapy for metastatic MSI-H colon cancer patients (156).